Compare CAPR & FOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CAPR | FOR |
|---|---|---|
| Founded | 2005 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2011 | 2007 |
| Metric | CAPR | FOR |
|---|---|---|
| Price | $30.60 | $25.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 4 |
| Target Price | ★ $41.38 | $31.75 |
| AVG Volume (30 Days) | ★ 921.3K | 117.8K |
| Earning Date | 01-01-0001 | 04-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.30 |
| Revenue | $22,270,465.00 | ★ $1,662,400,000.00 |
| Revenue This Year | N/A | $0.52 |
| Revenue Next Year | $17,308.50 | $7.72 |
| P/E Ratio | ★ N/A | $86.45 |
| Revenue Growth | N/A | ★ 10.14 |
| 52 Week Low | $4.30 | $18.00 |
| 52 Week High | $40.37 | $30.74 |
| Indicator | CAPR | FOR |
|---|---|---|
| Relative Strength Index (RSI) | 66.95 | 32.41 |
| Support Level | $22.09 | $24.05 |
| Resistance Level | $40.37 | $26.00 |
| Average True Range (ATR) | 1.84 | 0.92 |
| MACD | 0.17 | -0.53 |
| Stochastic Oscillator | 92.68 | 16.74 |
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
Forestar Group Inc is a residential lot development company engaged in land acquisition and development for the sale of finished single-family residential lots to local, regional, and national homebuilders. The company operates through a single real estate segment, which acquires land, installs infrastructure for residential communities, and generates all revenue from lot sales. Its communities mainly support entry-level, first-time move-up, and active-adult homes, with certain communities also marketed to build-to-rent operators. the company generally invests in entitled, short-duration projects that can be developed in phases to align lot production with market demand and support efficient capital deployment.